suMMxRY Efficacy of single-dose spectinomycin (TRO: 2 g intramuscularly) was compared with that ofaqueous procaine penicillin G (APPG: 4.8 x 106 units) plus 1 g ofprobenecid for treatment of gonococcal urethritis and cervicitis. Cure rates ofthe 210 patients who received TRO and 190 patients who received APPG were 97-6% and 91 1%, respectively. MICs of antibiotics were determined using the agar dilution method. Those isolates with MICs of APPG of < 1.0 ug/ml had low failure rates (2.9%), while strains with increased resistance to APPG (MICs > 1.0 pg/ml) had higher failure rates (24%). Treatment failures seen with TRO were not correlated to isolates with the higher MICs. Clinical results suggest TRO could be given for treatment ofgenital gonorrhoea in Puerto Rico due to the high prevalence of both chromosomally-mediated penicillin-resistant Neisseria gonorrhoeae (20%) and penicillinase-producing Neisseria gonorrhoeae (7.5%) strains and the high rate of failure seen with the use of APPG. The failure ofpenicillin and spectinomycin regimens in the clinical setting are known to vary according to geographic location.'`3 The reports of significant spatial and prevalence variation in the distribution of penicillinase-producing Neisseria gonorrhoeae (PPNG),' chromosomally mediated penicillin-resistant Neisseria gonorrhoeae (CMRNG) strains,9" and spectinomycin-resistant isolates'2-'5 are causes for concern among health-care practitioners world-wide.
Methodology

Patients
In this study, 533 patients with confirmed genital gonorrhoea by culture were enrolled from among persons visiting LACSTD during the period from 1982 to 1984. Patients were invited to participate ifthey had signs or symptoms of genital infection and gramnegative intracellular diplococci on smear of the discharge or were contact cases from a culture positive patient. Subjects were not invited to participate if pregnant or ifthey had a history ofallergy to penicillin or spectinomycin, evidence of coexistent syphilis, or had received antibiotics within the previous two weeks. All female and male subjects were between 18 and 54 years of age and gave written and informed consent. Clinical evaluation included a work-up for STD, including a clinical history, VDRL test, gramstain, KOH and wet mount smears, and pretreatment cultures in modified Thayer-Martin.
Patients were assigned by a randomised table to receive either 4-8 million units of intramuscular aqueous procaine penicillin G (APPG) plus 1 g of oral probenecid or 2 g of intramuscular spectinomycin (Trobicin). Treatment was initiated immediately after oral, genital and anal specimens were obtained for Penicillin and spectinomycin in urethritis and cervicitis with N gonorrhoeae: prevalence ofpenicillin resistance 343 years (range, 18-50 years); 129 were single and 58 were married; 165 were heterosexuals and 22 were male homosexuals. Information of social status and sexual preference was not recorded for seven males. Thus, both groups had similar characteristics. This was consistent with the randomised patient assignment used for this study. There were no serious adverse reactions or side effects seen in either treatment group. However, postgonoccocal urethritis (defined as 4 or more pus cells per field in a gram-stained smear x 1000 and a negative culture for Neisseria gonorrhoeae) was observed in 61 patients (27 spectinomycin; 34 APPG plus probenecid).
The follow-up results are shown in table 1. None of the patients who failed to be cured using either penicillin or spectinomycin admitted re-exposure between visits. All treatment failures with either antibiotic regimen were cured after being retreated with spectinomycin. The penicillin regimen was effective in 91-1% of the patients while the spectinomycin regimen was effective in 97.6%. A chi-square test of the frequencies of cure in each group confirmed that the observed difference was significant (X(1) = 8-31, p < 0-01). Although the sample size of women is small (47) for making conclusions, three of 26 patients treated with penicillin failed to cure and none of 21 treated with spectinomycin failed to cure. These observations among women followed the general trend of entire sample of 400 patients (see table 1 ).
The number of isolates and treatment failures in respond, while no treatment failures were observed with spectinomycin. In the CMRNG strains, 20% of those treated with penicillin failed to respond, whereas 5% of those treated with spectinomycin failed to respond.
The MIC50 and MIC90 to penicillin and spectinomycin were determined for 533 isolates (table 4). The MIC range and the MIC50 and MIC90 of penicillin and spectinomycin for the 400 isolates from patients with cures are identical. This finding means that the susceptibility pattern of the 400 isolates was similar to the total pool of isolates and similar cure rates will be expected with the 25% dropout patients. The number of CMRNG seen is high compared with that seen in the United States469t0 and in South Africa'9 but similar to other countries.' 16 
show a slight increase to 20.5%. Of the 369 non-betalactamase producing strains, 72-3% were found to require penicillin MICs of < 1.0 ig/ml, and they were classified either as penicillin susceptible (MICs < 0-06 pg/ml) or intermediate resistant strains (MICs > 0-06 pg/ml and < 1.0 ig/ml). This percentage is significantly higher than that reported for the United States462'23 but similar to other countries.' 1624
The incidence of PPNGs from 1981 to 1984 in Puerto Rico were 0.0%, 0.7%, 1 0%, and 8-6%, respectively. The presence of a fair number of PPNG isolates during the study was due to a large outbreak during 1984. Since control efforts are lacking for CMRNG and travel from areas of high prevalence caused periodic outbreaks of PPNG in Puerto Rico, a rapid increase in penicillin-resistant strains can be expected to occur at any time.
The treatment failures observed while using penicillin against strains with MICs < 1[0 ug/ml is very low and comparable to other reports.' The positive relationship of penicillin failures with CMRNG strains (MICs , 1-0 pg/ml) has been previously observed. 4 The presence of CMRNG strains should be of great concern for countries in the Carribean and Latin America that still used APPG regimen for gonorrhoea. Therefore, surveillance of these strains should be highly encouraged.'`In our opinion, a failure rate ofgreater than 5%, as seen with the APPG plus probenecid regimen in Puerto Rico, does not guarantee effective control of gonorrhoea.
The MIC50 and MIC90 to spectinomycin were higher than in other countries. 1'319 20 Perhaps this is due to the frequency of spectinomycin use in Puerto Rico for gonococcal infection. Like others whose work precedes ours, we were unable to relate spectinomycin treatment failures with in vitro spectinomycin susceptibility.' The spectinomycin regimen was also effective for PPNG, CMRNG (5% failure rate), and beta-lactamase negative strains, also reported by others.45811 '25 Factors contributing to treatment failure seen with spectinomycin in this study are still undefined since all isolates with MICs of 40-80 ig/ml responded to therapy. Our results showed that the in vitro break point for clinical resistance is probably higher than presently recommended. The few clinical failures with spectinomycin were probably due to reinfections or patients' immunological differences.
Recently, Boslego and coworkers26 reported the emergence of a substantial prevalence of clinical treatment failures caused by spectinomycin-resistant strains (MIC > 100 gg/ml) in a geographic region where spectinomycin had been used in the primary treatment ofgonococcal infection for only three years. Since the completion of the clinical study, we initiated a surveillance program to monitor the emergence of resistant strains to spectinomycin using sensitivity testing with 100 pg-spectinomycin disk and agar dilution. We have documented only a few sporadic (2) cases in a four year period, but a cautious approach to the widespread-use of spectinomycin is recommended. Public health officials in the area must remain vigilant in their surveillance effort and be alert to the introduction or emergence of spectinomycin-resistant strain.
There were no serious adverse reactions found with either the APPG plus probenecid or spectinomycin regimens. APPG plus probenecid could be used in Puerto Rico only in clinics that have surveillance for PPNG and CMRNG strains. However, spectinomycin could be given as an alternative for the treatment of genital 'gonorrhoea because of the high prevalence of CMRNG and PPNG strains and the high rate of failure seen with the use of penicillin. Current recommendations include a course of tetracycline or erythromycin for non-gonococcal urethritis (dual therapy) added to spectinomycin (or ceftri-
